Supplementary Figures 1-3, Tables 1-3 from Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAF&lt;sup&gt;V600E&lt;/sup&gt; Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression